Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2008.349 | Randomized Study of Pessary versus Expectant Management in Twins | Dr Hui Shuk Yi Annie |
| 2020.098 | Evaluation of risk factors associated with immunoprophylaxis failure of pregnant hepatitis B carriers in Hong Kong |
Dr. HUI Shuk Yi 許淑儀 |
| 2020.461 | The causes and timing of maternal mortality in Hong Kong – what have we missed? |
Dr. HUI Shuk Yi 許淑儀 |
| 2008.517 | A Randomised, Double-blind, Double-dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients with Chronic Obstructive Pulmonary Disease (COPD) | Professor Hui Shu Cheong, David |
| 2012.076 | A randomized controlled study on the effects of CPAP on visceral fat thickness, carotid intima-media thickness and adipokines in patients with Obstructive Sleep Apnoea Syndrome | Prof Hui Shu Cheong David |
| 2012.491 | An observational, multi-center, prospective, open-label study to assess the real-life treatment pattern for Chronic Obstructive Pulmonary Disease (COPD) in Hong Kong and its adherence to GOLD guideline | Prof Hui Shu Cheong David |
| 2010.572 | A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza | Prof. Hui Shu Cheong David |
| 2021.037 | A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS |
Prof. HUI Shu Cheong David 許樹昌教授 |
| 2025.143 | Chest X-ray Artificial Intelligence Assistance for Radiologist - A Proof of Concept | Prof. HUI Sai Kam |
| 2019.205 | The Effects of a Combined Acute and Chronic Aerobic Exercise Program on Autonomic and Cognitive Functions with Acute Psychological Stress |
Prof. HUI Sai Chuen 許世全 |
| 2018.508 | Development and validation of a risk model integrating post-radiotherapy plasma Epstein-Bar virus DNA and TNM stage for stratification of nasopharyngeal cancer to adjuvant therapy |
Dr. HUI Pun 許斌 |
| 2009.627 | Association between Physical Activity Knowledge, Physical Activity Behavior, and Age in Hong Kong Chinese Adults with Type 2 Diabetes | Dr Hui Pui Sze Grace |
| 2014.223 | The Association between Black Carbon/Ground-level Ozone and Acute Respiratory Effects in Healthy Young Adult Cyclists- A Crossover Study in Hong Kong | Miss HUI Nga Ting |
| 2012.203 | The validation of the screening programme for diabetic retinopathy | Dr Hui Ming Tung Eric |
| 2017.294 | Retrospective analysis of Candida parapsilosis complex fungaemia. |
Dr. HUI Mamie 許明媚 |
| 2025.080 | Comparison of suicidal fall and accidental fall patient characteristics in fall from height patients | Dr. HUI Lok Hin |
| 2019.616 | Economic evaluation on breastfeeding promotion in Hong Kong |
Dr. HUI Lai Ling 許麗玲 |
| 2019.492 | A study on the view of Hong Kong parents on secondary use of dried blood spots in newborn screening program - implications on evidence-based policies |
Dr. HUI Lai Ling 許麗玲 |
| 2017.456 | A Retrospective Evaluation of the use of Crisis Packs in Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in a local hospital |
Mr. HUI Kei Shing 許基誠 |
| 2011.319 | Knowledge, Attitude and Practice of Chronic Disease Patient on Counterfelt Drugs buying in Hong Kong | Mr Hui Ka Chun |
| 2013.132 | Glycogen Storage Disease Type 1 in Hong Kong: diagnosis, clinical course and outcome | Dr Hui Joannie |
| 2016.567 | International Network on Neurotransmitter related Disorder (iNTD) Registry |
Dr. HUI Joannie 許鍾妮 |
| 2015.098 | Rare Disease Registry Program | Dr. HUI Joannie |
| 2016.055 | In-depth study of the cost-effectiveness of the Risk Assessment and Management Programme for Hypertension (RAMP-HT) for patients with uncontrolled hypertension in primary care in Hong Kong |
Dr. HUI Eric Ming Tung 許明通 |
| 2013.423 | Evaluation of Quality of Care : Risk Assessment and Management Programme - Hypertension, Hospital Authority | Dr. HUI Eric Ming Tung |
| 2020.337 | Development and validation of HA electronic Frailty Index (HA-eFI) |
Dr. HUI Elsie 許鷗思 |
| 2007.101 | Immune Responses in Nasopharyngeal Carcinoma | Dr. HUI Edwin Pun |
| 2011.257 | A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy | Dr. HUI Edwin Pun |
| 2008.131 | A Multi-center Study of the Therapeutic Role of Continuous Positive Airway Pressure Therapy on Ischemic Stroke Survivors with Obstructive Sleep Apnoea Syndrome | Prof Hui David Shu-Cheong |
| 2011.215 | A randomized controlled study assessing the role of an ambulatory approach versus the conventional approach in managing moderate to severe obstructive sleep apnoea syndrome | Prof Hui David Shu Cheong |
| 2010.605 | A 6-month, double-blind, randomised, multicenter, multinational trial to investigate the effect of 500 | Professor Hui David Shu Cheong |
| 2013.213 | A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD | Prof. HUI David Shu Cheong |
| 2008.286 | A Randomized, Parallel, Controlled Study to Evaluate the Role of Pretreatment Drug Susceptibility Tests in the Selection of Regimens of Chemotherapy for Retreatment of Relapsed Pulmonary TB in Guangzhou | Prof Hui David Shu Cheong |
| 2010.267 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older | Prof. HUI David Shu Cheong |
| 2010.266 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older | Prof. HUI David Shu Cheong |
| 2011.470 | A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared with Aclidinium Bromide, Formoterol Fumarate and Placebo for 24 Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD) | Professor Hui David Shu Cheong |
| 2007.072 | Management and Clinical Progress of Patients with Severe Influenza - A Prospective Observational Study | Prof. HUI David Shu Cheong |
| 2011.214 | The effects of CPAP on twist mechanics of the left ventricle in patients with moderate to severe Obstructive Sleep Apnoea | Prof Hui David Shu Cheong |
| 2025.022 | BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist | Prof. HUI David Shu Cheong |
| 2025.318 | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study) | Prof. HUI David Shu Cheong |
| 2024.628 | A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE) | Prof. HUI David Shu Cheong |
| 2024.240 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | Prof. HUI David Shu Cheong |
| 2024.428 | The disease burden of RSV infection in Hong Kong | Prof. HUI David Shu Cheong |
| 2024.207 | A study to evaluate the consistency of oscillometry and spirometry test results in patients with confirmed or suspected asthma or COPD |
Prof. Hui David Shu Cheong 許樹昌 |
| 2024.481 | SA-BioPercept study: A survey study on biologics initiation from the perspective of moderate-tosevere asthma patients | Prof. HUI David Shu Cheong |
| 2020.122 | Effect of long term Clarithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis in Asian populations | Prof. HUI David Shu Cheong |
| 2018.185 | A randomized controlled trial of adjunctive sirolimus and oseltamivir versus oseltamivir alone for treatment of influenza |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.508 | Clinical Characteristics of COPD Patients in Hong Kong – An analysis of the Prince of Wales Hospital COPD patients |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2020.114 | Assessing the risk of exposure and spread of the SARS-CoV-2 virus in the hospital environment |
Dr. HUI David Shu Cheong 許樹昌 |
| 2019.634 | Screening for lung cancer in subjects with family history of lung cancer. |
Prof. HUI David Shu Cheong 許樹昌教授 |
Page 160 of 265.